Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Mutations in the tumor suppressor p53 are common in many cancers.
• Targeting these specific mutations could offer new therapeutic strategies.
• Developing highly selective reagents is crucial for mutation-specific targeting.

Purpose of the Study:

• To generate and characterize monoclonal antibodies against common p53 hotspot mutants (R175H, R248Q, R273H).
• To evaluate the specificity and utility of these antibodies for detecting p53 mutations in cancer.

Main Methods:

• Generation of monoclonal antibodies against specific p53 mutants.
• Validation using immunoblotting, immunoprecipitation, and immunofluorescence assays.
• Assessment of antibody specificity against wild-type p53 and other mutants.
• Testing clinical utility via immunohistochemistry on human tumor microarrays.

Main Results:

• Successfully generated antibodies that specifically recognize R175H, R248Q, and R273H p53 mutants.
• Demonstrated no cross-reactivity with wild-type p53 or other p53 variants.
• Confirmed antibody specificity even for mutations at the same amino acid position.
• Showcased the diagnostic potential of these antibodies in human tumor samples.

Conclusions:

• Reproducible generation of mutation-specific antibodies against p53 alterations is feasible.
• These antibodies are valuable tools for diagnosing specific p53 mutations in cancer.
• The findings support the potential application of these reagents in targeted cancer therapies.